KRP-297

• UNSPSC Description:

  KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.

• Target Antigen:

  PPAR

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/krp-297.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC(CC2SC(NC2=O)=O)=CC=C1OC)NCC3=CC=C(C=C3)C(F)(F)F

• Molecular Weight:

  438.42

• References & Citations:

  [1]Murakami K, Tobe K, Ide T, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes. 1998;47(12):1841-1847. |[2]Kochansky CJ, Rippley RK, Yan KX, et al. Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans. Drug Metab Dispos. 2006;34(9):1457-1461.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  213252-19-8